Nvidia, Micron Surge in Pre-Market Trading as Altimmune Plunges 62% on Trial Results; Crypto Policy Boosts Sentiment

·

The U.S. stock market opened with strong momentum on June 26, 2025, as tech giants Nvidia and Micron led pre-market gains amid positive earnings reports and advancing AI-driven semiconductor demand. Meanwhile, biotech firm Altimmune tumbled 62% following disappointing clinical trial results, while cryptocurrency-related stocks reacted to new policy developments. This article breaks down the key market movements, corporate updates, and macroeconomic signals shaping investor sentiment.


Pre-Market Market Overview and Macroeconomic Indicators

On June 26, 2025, U.S. stock index futures showed upward momentum despite mixed economic signals. The Dow Jones, S&P 500, and Nasdaq 100 futures all rose, reflecting optimism in the technology sector. However, the gains slightly narrowed after the Labor Department reported that initial jobless claims for the week ending June 21 came in at 236,000—below the expected 245,000 and revised prior figure of 246,000.

This stronger-than-expected labor data underscored ongoing economic resilience but also heightened sensitivity to Federal Reserve policy decisions. Fed Chair Jerome Powell recently noted during a June 24 congressional hearing that data reliability has become a growing concern for monetary policy formulation. Boston Fed President Susan Collins echoed this sentiment on June 25, expressing a preference for rate cuts later in the year but warning that trade tariffs could reignite inflationary pressures.

Market structure dynamics are also at play. Nomura strategist Charlie McElligott projected that volatility-controlled funds could inject over $100 billion into U.S. equities in the coming month—a bullish signal for large-cap tech stocks.

In pre-market trading, AMD gained nearly 3%, Nvidia and Micron Technology each rose about 2%, while Chinese ADRs were mixed: Li Auto gained over 1%, while NetEase dipped close to 1%.

👉 Discover how market-moving events can impact your investment strategy—explore real-time insights here.


Nvidia’s Robotics Vision Fuels Growth Momentum

Nvidia’s pre-market rally pushed its stock toward $140, maintaining its position as the world’s most valuable company with a market capitalization of approximately $3.77 trillion. At its June 25 shareholder meeting, CEO Jensen Huang emphasized that robotics technology represents the next major frontier after artificial intelligence.

“Robotics is the next trillion-dollar opportunity,” Huang stated. “Autonomous vehicles will be the first major commercial application, unlocking a multi-trillion-dollar market.”

While Nvidia’s automotive and robotics segment contributed $567 million in Q1 2025—up 72% year-over-year and accounting for just 1% of total revenue—the long-term synergy between its data center GPUs and autonomous driving platforms is drawing strong investor confidence.

Despite its impressive growth trajectory, Nvidia trades at a forward P/E ratio above 70, signaling elevated valuation risk. Any slowdown in AI infrastructure spending or delays in robotics adoption could trigger a correction.

Key Financial Highlights: Nvidia Q1 2025


Micron Technology Soars on Record DRAM Demand

Micron Technology surged more than 2% in pre-market trading, approaching $150 per share, after delivering robust third-quarter results for its fiscal year 2025 (ended May 29). The company reported revenue of $9.3 billion—up 37% year-over-year and exceeding analyst expectations of $8.85 billion.

Adjusted earnings per share reached $1.91, surpassing the consensus estimate of $1.60. Notably, DRAM revenue hit an all-time high, driven by surging demand from AI data centers.

Looking ahead, Micron provided an optimistic fourth-quarter outlook:

CEO Sanjay Mehrotra highlighted that AI is fueling a recovery in the memory chip market and announced increased investment in High Bandwidth Memory (HBM)—a critical component for advanced AI processors.

Analysts project that HBM could account for up to 20% of Micron’s revenue by fiscal 2026. However, investors should remain cautious about cyclical risks inherent in the semiconductor industry.

Micron Financial Snapshot (Fiscal Q3 2025)

👉 Stay ahead of semiconductor trends and AI infrastructure plays with timely market intelligence.


Altimmune Crashes 62% After Failed MASH Trial

Biotech stock Altimmune plummeted 62% in pre-market trading to around $3 following disappointing results from its Phase IIb trial of pemvidutide for treating MASH (Metabolic dysfunction-associated steatohepatitis).

While the drug demonstrated significant weight loss—5.0% in the 1.2mg group and 6.2% in the 1.8mg group compared to just 1.0% in the placebo group—it failed to show statistically significant improvement in liver fibrosis:

The lack of clear therapeutic advantage over placebo triggered a massive sell-off, especially given the intense competition in the obesity drug space from industry leaders like Eli Lilly and Novo Nordisk, whose GLP-1 agonists dominate the market.

CEO Vipul Agarwal maintained that the weight-loss efficacy supports further development of pemvidutide for obesity indications. However, without a breakthrough in liver disease applications, Altimmune faces an uphill battle for market relevance.


Cryptocurrency Policy Shift Sparks Market Reaction

Cryptocurrency-related stocks showed mixed performance despite a major policy development. On June 25, William Pulte, director of the Federal Housing Finance Agency (FHFA), announced that Fannie Mae and Freddie Mac will explore accepting cryptocurrency as collateral in mortgage lending—an initiative aligned with former President Trump’s vision of creating a “crypto capital” in the U.S.

This move could open access to an estimated $230 billion in federal housing loans for digital asset holders, signaling growing institutional acceptance of crypto assets.

However, not all crypto stocks benefited:

The divergence highlights investor sensitivity to capital structure decisions even amid favorable regulatory winds.


Editor’s Summary: Balancing Growth and Risk

Pre-market trading on June 26 reflected a market buoyed by strong tech fundamentals and forward-looking policy support for innovation sectors like AI and digital assets. Nvidia and Micron’s rallies underscore sustained demand for high-performance computing infrastructure.

Yet risks remain: elevated valuations in tech, cyclicality in semiconductors, clinical trial volatility in biotech, and equity dilution concerns in crypto mining firms all warrant caution.

Macro uncertainties—including Fed policy direction and inflation risks from trade policies—add layers of complexity. Investors should balance exposure to high-growth themes with risk management strategies.


Frequently Asked Questions

Q: Why did Nvidia's stock rise despite robotics contributing only 1% of revenue?
A: Investors are pricing in future growth potential. The synergy between AI chips and autonomous robotics platforms positions Nvidia as a foundational player in next-gen computing.

Q: What is HBM, and why is it important for Micron?
A: High Bandwidth Memory (HBM) is a type of advanced DRAM used in AI accelerators. As AI models grow larger, HBM demand is surging—making it a strategic growth vector for memory manufacturers like Micron.

Q: Can Altimmune recover from its MASH trial failure?
A: Yes, but likely only through success in obesity treatment trials. Without differentiation in liver disease outcomes, its path to profitability remains uncertain.

Q: How might cryptocurrency as mortgage collateral work?
A: Lenders could accept crypto holdings as part of a borrower’s net worth assessment or allow them as loan collateral—subject to valuation and volatility controls.

Q: Is Bit Digital’s stock drop permanent?
A: Not necessarily. The selloff reflects short-term dilution fears. If Ethereum appreciates significantly post-purchase or mining margins improve, sentiment could rebound.

Q: Are AI-driven semiconductor gains sustainable?
A: In the near term, yes—driven by cloud infrastructure buildouts. But long-term sustainability depends on innovation cycles and global supply-demand balance.


Key Market Events – June 24–25, 2025

FHFA directs Fannie Mae and Freddie Mac to study cryptocurrency as mortgage collateral—boosting crypto sentiment.

Nvidia CEO Jensen Huang declares robotics a "multi-trillion-dollar opportunity" at shareholder meeting; stock rises pre-market.

Micron reports record DRAM sales and strong forward guidance; shares climb over 2%.

Altimmune’s pemvidutide fails to meet fibrosis improvement goals in MASH trial; stock crashes 62%.

Former President Trump reveals he has shortlisted candidates for Fed Chair—reigniting speculation about leadership change.


Expert Insights

Jensen Huang, CEO of Nvidia: “Robotics and AI are shaping our future. Autonomous vehicles will lead a multi-trillion-dollar transformation.”

Sanjay Mehrotra, CEO of Micron: “AI is driving a new era of memory demand. Our HBM investments will strengthen our leadership.”

Vipul Agarwal, CEO of Altimmune: “Though MASH results were not statistically significant, the weight loss data gives us confidence to continue development.”

William Pulte, FHFA Director: “Integrating cryptocurrency into mortgage finance is a step toward modernizing America’s financial infrastructure.”

Charlie McElligott, Nomura Strategist: “Volatility-targeting funds may add over $100B to equities—tech stocks have room to run despite macro risks.”


👉 Capitalize on market shifts with advanced tools and real-time data—start exploring today.